kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
79
JPY
0
(0.00%)
Apr 30, 10:16 am JST
0.49
USD
Apr 29, 9:16 pm EDT
Result
PTS
outside of trading hours
79.6
Apr 30, 10:16 am JST
Summary Chart Historical News Financial Result
PER
PBR
1.33
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
79 JPY 0.49 USD
Previous Close Apr 28
79 JPY 0.49 USD
High Apr 30, 9:02 am
80 JPY 0.49 USD
Low Apr 30, 9:00 am
79 JPY 0.49 USD
Volume
193,100
Trading Value
0.02B JPY 0.10M USD
VWAP
79.0 JPY 0.49 USD
Minimum Trading Value
7,900 JPY 49 USD
Market Cap
4.29B JPY 0.03B USD
Number of Trades
41
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
414
1-Year High Mar 3, 2026
9,798
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 9,242,500
Apr 17, 2026 0 9,133,700
Apr 10, 2026 0 8,984,700
Apr 3, 2026 0 8,898,900
Mar 27, 2026 0 8,920,600
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.